Net loss for the three months ended March 31, 2026, was $4.5 million, compared to a net loss of $46.4 million in the same period of 2025. Net revenue for the quarter was $0.1 million, reflecting early commercial sales of LYTENAVA in Europe. Operating expenses for the quarter were $14.0 million, driven by R&D and commercialization costs. The company maintains a working capital deficit and has expressed substantial doubt regarding its ability to continue as a going concern. As of March 31, 2026, cash and cash equivalents totaled $7.7 million.